Skip to main content
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale logoLink to The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale
. 2008 Nov-Dec;19(6):409–412. doi: 10.1155/2008/848045

Genotypic investigation of Clostridium difficile in Prince Edward Island

H Martin 1, LP Abbott 2, DE Low 3, B Willey 3, M Mulvey 4, J Scott Weese 5,
PMCID: PMC2663471  PMID: 19436570

Abstract

Clostridium difficile is an important cause of disease in Canada; however, little information is available about the disease in the Maritime provinces. The objective of the present study was to characterize C difficile isolates obtained from people hospitalized with C difficile infection in Prince Edward Island. One hundred twenty-six C difficile ELISA toxin-positive stool samples were obtained and cultured using an enrichment protocol. C difficile was isolated from 105 of 126 (83%) samples. Twenty-two different ribotypes were identified. The most common ribotype, ribotype W, was a North American pulsotype 2 (NAP2), toxinotype 0 strain, which represented 18% of isolates. The next most common ribotype was a NAP1, toxinotype III strain, which accounted for 11% of isolates. Ribotype 027/NAP1 only accounted for five (4.7%) isolates. Forty-five per cent of isolates possessed genes encoding production of binary toxin. Three different ribotypes, all NAP1, toxinotype III strains, had a frameshift mutation in the tcdC gene (Δ117), while one isolate (ribotype 078, NAP4, toxinotype V) had a truncating mutation (C184T) in the tcdC gene.

Keywords: Clostridium difficile, Microbiology, Molecular epidemiology


Clostridium difficile is an important cause of disease in Canada; it is responsible for both large outbreaks and endemic disease (13). Because of the significance of this pathogen and the apparent change in epidemiology noted in various countries (4,5), the need for microbiological surveillance is becoming clear. Recently, large studies of isolates from across Canada (6) and Ontario (7) were performed, and they described the types of C difficile that predominate in different regions. Studies, such as the present one, are important for the evaluation of the molecular epidemiology of C difficile infection (CDI) and to provide important microbiological data for comparison with epidemiological data. They also provide baseline information so that future changes in clinical aspects of CDI can be related to changes in predominant strains. The emergence and dissemination of a purportedly hypervirulent strain, designated ribotype 027 or North American pulsotype 1 (NAP1), has been associated with outbreaks and severe disease in various regions (2,8,9); however, little information about the disease is available in the Maritime provinces, including Prince Edward Island (PEI). The objective of the present study was to characterize C difficile isolates obtained from people hospitalized with CDI in PEI.

METHODS

Stool samples were submitted from 126 consecutive individuals diagnosed with CDI at Queen Elizabeth Hospital, Charlottetown, PEI, between October 31, 2005, and January 8, 2007, through a positive ELISA for C difficile toxins A and/or B (C difficile Tox A/B II, TechLab Inc, USA). Samples were stored aerobically at 4°C before processing. Enrichment culture was performed using an adaptation of the protocol described by Arroyo et al (10), with a seven-day enrichment in C difficile moxalactam norfloxacin with 0.1% sodium taurocholate broth before inoculation onto C difficile moxalactam norfloxacin agar. Plates were incubated for 48 h to 120 h at 37°C in an anaerobic chamber. Colonies with the characteristic morphology, odour and Gram stain appearance were subcultured onto Columbia blood agar and confirmed as C difficile by colony and Gram stain morphology and production of l-proline-aminopeptidase (Pro Disc, Remel, USA).

Ribotyping was performed according to the methods described by Bidet et al (11). In situations in which the ribotype was known to be a recognized international ribotype from the Public Health Laboratory Service – Anaerobe Reference Unit (University Hospital of Wales, Cardiff, United Kingdom) by previous typing of reference strains, the appropriate numerical designation (ie, 027) was used. Otherwise, a letter that corresponded to an internal nomenclature for types not validated with the Public Health Laboratory Service reference strains was used. Detection of genes encoding toxin A (tcdA) and toxin B (tcdB) was performed by polymerase chain reaction (PCR) as previously described (12,13). CDT (cdtB) detection was performed using real-time PCR based on the conventional PCR method of Stubbs et al (14). The presence of a deletion in the tcdC gene was investigated on a representative isolate from each PCR ribotype by PCR amplification of the tcdC gene following the methods outlined by Spigaglia and Mastrantonio (15). The PCR product was purified and sequenced. A representative isolate from each PCR ribotype was also typed by toxinotyping (16). Ribotypes accounting for three or more isolates were also typed using pulsed-field gel electrophoresis (PFGE) (17) and classified as a NAP type or, in situations in which the PFGE pattern was not consistent with any of the NAP groups, the individual PFGE pattern number was reported.

RESULTS

C difficile was isolated from 105 of 126 (83%) samples. Twenty-two different ribotypes were identified. Details regarding strains represented by two or more isolates are presented in Table 1. Overall, toxinotype 0 strains were most common, accounting for 13 ribotypes and 54 (51%) isolates. Three distinct ribotypes were classified as NAP2. Toxinotype III strains accounted for four ribotypes and a total of 30 (30%) isolates. Ribotype 027/NAP1 accounted for five of these isolates, for an overall prevalence of 4.7%. The most common toxinotype III strain was a NAP1 strain classified as ribotype N. One toxinotype III strain was not associated with any of the NAP types; however, it had the same toxin gene profile as NAP1 and possessed the same tcdC gene alteration.

TABLE 1.

Characteristics of the most common Clostridium difficile isolates (n=99) recovered from people with C difficile infection in Prince Edward Island (n=105)

Ribotype Toxin A Toxin B CDT tcdCdeletion tcdCmutation PFGE Toxinotype Isolates (n) Isolates (%)
W + + NAP2 0 19 18.0
N + + + 18 bp Δ117 NAP1 III 12 11.4
C + + + 0012 IX 12 11.4
AN + + NAP2 0 12 11.4
Y + + + 18 bp Δ117 0098 III 11 10.5
027 + + + 18 bp Δ117 NAP1 III 5 4.7
L + + 0042 0 5 4.7
017 + 0117 VIII 3 2.9
AK + + NAP6 0 3 2.9
078 + + + 39 bp C184T NAP8 V 3 2.9
AA + + NAP2 0 3 2.9
M + + NAP2 0 3 2.9
A + + + 0012 IX 2 1.9
AD + + + 18 bp Δ117 NAP1 III 2 1.9
AI + + ND 0 2 1.9
0 + + ND 0 2 1.9

bp Base pair; NAP North American pulsotype; ND Not determined; PFGE Pulsed-field gel electrophoresis

Overall, the toxin profile A+B+CDT– was the most common accounting for 52% of isolates, while toxin profiles A+B+CDT+ and A–B+CDT– accounted for 45% and 3%, respectively. Five different ribotypes, accounting for 33 (31%) isolates, possessed a deletion in the tcdC. Four types, all toxinotype III, had an 18 base pair deletion plus a single nucleotide deletion at position 117 that introduced a frameshift mutation (Δ117). A different tcdC alteration was present in one strain – a toxinotype V strain with a 39 base pair tcdC gene deletion known internationally as ribotype 078 and with a PFGE fingerprint that corresponded to NAP8. It contained a nonsense mutation at position 184 (C184T) of the tcdC gene. These mutations were not identified in isolates with an intact tcdC gene.

DISCUSSION

This is the first genotypic evaluation of C difficile in PEI. The predominance of ribotype W/NAP2 was not surprising because this ribotype is also the most common strain in Ontario (7); NAP2 was the most common clone in the Canadian Nosocomial Infection Surveillance Program (6). While the predominance of W/NAP2 was consistent with other Canadian studies, there were also significant differences in the strain distribution. Ribotype 027 only accounted for 4.7% of isolates, compared with 19.4% in Ontario (7). However, two other ribotypes were classified as NAP1, for a total prevalence of 18%, which is similar to the prevalence of NAP1 isolates in the Canadian Nosocomial Infection Surveillance Program study (27%) (6) and in Ontario (31%) (7). The most common NAP1 ribotype, ribotype N, only accounted for 6.6% of isolates in Ontario, but was the second most common strain in the present study. NAP1/ribotype 027 strains may be of particular concern because of reports of severe disease and outbreaks attributed to this strain (18,19); although some conflicting data are present (20). The mechanism of hypervirulence associated with these strains was originally thought to be a deletion in the tcdC gene, a negative regulator of toxin A and B production, because strains possessing this deletion produced much higher levels of toxins in vitro (19). However, it has been subsequently demonstrated that strains with this deletion can produce a functional tcdC protein (21), and an upstream deletion (Δ117) in tcdC is more likely the cause of increased toxin production by NAP1/ribotype 027 because it encodes a stop codon (22,23). All NAP1 ribotypes possessed this tcdC mutation.

Ribotype 078/NAP8, a toxinotype V strain possessed a 39 base pair tcdC deletion and had a different tcdC mutation. This mutation, C184T, is a nonsense mutation that should result in severe truncation of the tcdC protein (23). The effect of this mutation on toxin production has not been clearly demonstrated, but toxinotype V strains have been reported to produce more toxins in vitro than toxinotype 0 strains, but less than toxinotype III strains (24). While uncommon, toxinotype V strains may be of concern because recent reports (24,25) have described an increase in CDI caused by the most common toxinotype strain – ribotype 078. Ongoing monitoring of the role of this strain in disease is indicated. The high prevalence of the toxinotype IX strain, ribotype C, was unexpected because this toxinotype is uncommon (26); toxinotype IX strains accounted for less than 1% of strains in Ontario (7). While it possessed a normal tcdC gene, this strain contained genes encoding production of binary toxin, which may be an important virulence factor (27). Overall, the prevalence of strains possessing binary toxin genes (45%) was higher than has historically been reported (28,29), but is consistent with recent reports describing dramatic increases in the prevalence of these strains internationally (6,7,30). The toxin AB+ ribotype 017 was present, but uncommon, as is typically reported. Despite its inability to produce toxin A, this strain is clinically relevant and has been associated with outbreaks of CDI (31).

Consensus has not been achieved regarding optimal typing methodologies or combinations of methodologies. While PFGE is regarded as more discriminatory than ribotyping (32,33), this may not be the case when PFGE results are interpreted in the context of epidemic clones (NAP types). Multiple different ribotypes were identified within individual NAP clones, indicating that, as applied, ribotyping is more discriminatory. However, when individual PFGE patterns are evaluated in addition to NAP type designation, the discriminatory power of PFGE increases. PFGE has some clear advantages over ribotyping, including standardized methods and interpretation, and excellent interlaboratory reproducibility. However, because ribotyping is much easier and more amenable to rapid typing of large numbers of isolates, it is widely used. Toxinotyping is a less discriminatory technique that is useful as a secondary test and for broader comparison of isolates. It is not useful at the hospital level because of poor discriminatory power, but does provide useful information in larger epidemiological studies. Combinations of methods may be ideal for broad epidemiological studies and for evaluation of new strains.

The present study has provided the first evaluation of C difficile isolates in PEI, and has demonstrated both similarities and differences in the isolate types found in PEI versus other areas of Canada. Studies, such as the present one, provide important baseline information for future clinical and microbiological surveillance, which may be an important factor for elucidation of the pathogenesis and evaluation of infection prevention and control measures for this important pathogen.

Acknowledgments

The authors thank Dave Boyd and Tim Du for the pulsed-field gel electrophoresis analysis.

REFERENCES

  • 1.Pépin J, Valiquette L, Alary M, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ. 2004;171:466–72. doi: 10.1503/cmaj.1041104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.McDonald L, Killgore G, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–41. doi: 10.1056/NEJMoa051590. [DOI] [PubMed] [Google Scholar]
  • 3.Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect. 2007;13:1058–64. doi: 10.1111/j.1469-0691.2007.01793.x. [DOI] [PubMed] [Google Scholar]
  • 4.Centers for Disease Control and Prevention Severe Clostridium difficile-associated disease in populations previously at low risk –four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1201–5. [PubMed] [Google Scholar]
  • 5.Kuijper E, van Dissel J, Wilcox M. Clostridium difficile: Changing epidemiology and new treatment options. Curr Opin Infect Dis. 2007;20:376–83. doi: 10.1097/QCO.0b013e32818be71d. [DOI] [PubMed] [Google Scholar]
  • 6.Mulvey M, Miller M, Gravel D, et al. The 2nd International Clostridium difficile Symposium. Maribor: Jun 6 to 9, 2007. Molecular epidemiology of Clostridium difficile in Canadian hospitals, 2004–2005. [Google Scholar]
  • 7.Martin H, Staempfli H, Willey B, et al. The 2nd International Clostridium difficile Symposium. Maribor: Jun 6 to 9, 2007. Characterization of Clostridium difficile from patients in Ontario hospitals. [Google Scholar]
  • 8.Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007;102:2781–8. doi: 10.1111/j.1572-0241.2007.01539.x. [DOI] [PubMed] [Google Scholar]
  • 9.Loo V, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9. doi: 10.1056/NEJMoa051639. [DOI] [PubMed] [Google Scholar]
  • 10.Arroyo L, Rousseau J, Willey B, et al. Use of a selective enrichment broth to recover Clostridium difficile from stool swabs stored under different conditions. J Clin Microbiol. 2005;43:5341–3. doi: 10.1128/JCM.43.10.5341-5343.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bidet P, Barbut F, Lalande V, Burghoffer B, Petit J. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett. 1999;175:261–6. doi: 10.1111/j.1574-6968.1999.tb13629.x. [DOI] [PubMed] [Google Scholar]
  • 12.Kato H, Kato N, Watanabe K, et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol. 1998;36:2178–82. doi: 10.1128/jcm.36.8.2178-2182.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lemee L, Dhalluin A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol. 2004;42:5710–4. doi: 10.1128/JCM.42.12.5710-5714.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett. 2000;186:307–12. doi: 10.1111/j.1574-6968.2000.tb09122.x. [DOI] [PubMed] [Google Scholar]
  • 15.Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol. 2002;40:3470–5. doi: 10.1128/JCM.40.9.3470-3475.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol. 1998;36:2240–7. doi: 10.1128/jcm.36.8.2240-2247.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Klaassen CH, van Haren HA, Horrevorts AM. Molecular fingerprinting of Clostridium difficile isolates: Pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol. 2002;40:101–4. doi: 10.1128/JCM.40.1.101-104.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hubert B, Loo V, Bourgault A, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C difficile-associated disease in Quebec. Clin Infect Dis. 2007;44:238–44. doi: 10.1086/510391. [DOI] [PubMed] [Google Scholar]
  • 19.Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84. doi: 10.1016/S0140-6736(05)67420-X. [DOI] [PubMed] [Google Scholar]
  • 20.Morgan OW, Rodrigues B, Elston T, et al. Clinical severity of Clostridium difficile PCR ribotype 027: A case-case study. PLoS ONE. 2008;3:e1812. doi: 10.1371/journal.pone.0001812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol. 2007;64:1274–88. doi: 10.1111/j.1365-2958.2007.05739.x. [DOI] [PubMed] [Google Scholar]
  • 22.MacCannell D, Louie T, Gregson D, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006;44:2147–52. doi: 10.1128/JCM.02563-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Curry SR, Marsh JW, Muto CA, O’Leary MM, Pasculle AW, Harrison LH. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol. 2007;45:215–21. doi: 10.1128/JCM.01599-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Jhung MA, Thompson A, Killgore G, et al. The 2nd International Clostridium difficile Symposium. Maribor: Jun 6 to 9, 2007. An emerging Clostridium difficile toxinotype in humans and food animals. [Google Scholar]
  • 25.Goorhuis A, Debast SB, van Leengoed LA, et al. Clostridium difficile PCR ribotype 078: An emerging strain in humans and in pigs? J Clin Microbiol. 2008;46:1157. doi: 10.1128/JCM.01536-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Barbut F, Mastrantonio P, Delmée M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect. 2007;13:1048–57. doi: 10.1111/j.1469-0691.2007.01824.x. [DOI] [PubMed] [Google Scholar]
  • 27.Barbut F, Decré D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54:181–5. doi: 10.1099/jmm.0.45804-0. [DOI] [PubMed] [Google Scholar]
  • 28.Gonçalves C, Decré D, Barbut F, Burghoffer B, Petit J. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004;42:1933–9. doi: 10.1128/JCM.42.5.1933-1939.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rupnik M, Grabnar M, Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe. 2003;9:289–94. doi: 10.1016/j.anaerobe.2003.09.002. [DOI] [PubMed] [Google Scholar]
  • 30.Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis. 2007;45:695–703. doi: 10.1086/520984. [DOI] [PubMed] [Google Scholar]
  • 31.Alfa M, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2706–14. doi: 10.1128/jcm.38.7.2706-2714.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bidet P, Lalande V, Salauze B, et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol. 2000;38:2484–7. doi: 10.1128/jcm.38.7.2484-2487.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Northey G, Gal M, Rahmati A, Brazier J. Subtyping of Clostridium difficile PCR ribotype 001 by REP-PCR and PFGE. J Med Microbiol. 2005;54:543–7. doi: 10.1099/jmm.0.45989-0. [DOI] [PubMed] [Google Scholar]

Articles from The Canadian Journal of Infectious Diseases & Medical Microbiology are provided here courtesy of Wiley

RESOURCES